Mon Nov 17 22:00:00 UTC 2025: Here’s a summary and a news article based on the provided text:
Summary:
Novo Nordisk is lowering prices for its popular weight loss and diabetes drugs, Wegovy and Ozempic, for cash-paying customers. This decision comes amid increased competition from rival Eli Lilly and compounding pharmacies, as well as pressure from the Trump administration to lower drug costs. The company is offering discounted starter doses and reduced monthly prices through its direct-to-consumer channels and partnerships with retailers like Costco and Weight Watchers. This move aims to boost sales in the US self-pay market, where a significant portion of users currently pay out-of-pocket due to limited insurance coverage for weight loss drugs. Other companies such as Eli Lilly are similarly reducing the prices for their weight loss drugs, such as Zepbound.
News Article:
Novo Nordisk Slashes Prices for Wegovy and Ozempic Amid Market Competition, Trump Administration Pressure
[City, State] – In a move aimed at attracting cash-paying customers and countering growing competition, Novo Nordisk announced Monday it is lowering the prices of its blockbuster weight loss and diabetes drugs, Wegovy and Ozempic. The price cuts come as the company faces pressure from rival Eli Lilly, compounding pharmacies offering cheaper alternatives, and ongoing efforts by the Trump administration to reduce prescription drug costs.
Effective immediately, Novo Nordisk is offering the first two monthly doses of Wegovy and Ozempic for $199 to those paying out-of-pocket, with the discount expiring at the end of March. Additionally, the company is reducing the monthly price of both medications to $349 for other self-pay patients, a decrease from the previous $499.
These discounted prices will be available through Novo Nordisk’s direct-to-consumer channels and its partnerships with major retailers like Costco, GoodRx, and Weight Watchers, as well as through over 70,000 retail pharmacies.
“There’s a lot of interest in direct pay, self-pay,” said Dave Moore, executive vice president of US operations for Novo Nordisk, highlighting the company’s focus on reaching individuals who lack insurance coverage for weight loss medications. “We know that’s an interest of people living with obesity.”
The announcement follows Novo Nordisk’s recent agreement with the Trump administration to expand access to Medicare and Medicaid markets in exchange for further price reductions. Under the agreement, consumers buying injectable GLP-1 medications directly from the companies will pay an average of $350 per month to start, though the drugmakers have committed to reducing the price to about $250 over the next two years. If oral GLP-1 tablets are approved by the US Food and Drug Administration, the lowest dose will cost $149.These prices will be available when TrumpRx, the administration’s direct-to-consumer online platform, launches in early 2026.
Pharmaceutical analyst Evan Seigerman of BMO Capital Markets noted that Novo Nordisk’s pricing adjustment likely reflects a need to regain market share amid increasing competition. Eli Lilly, a significant player in the weight loss drug market, has similarly cut the price of its GLP-1 weight loss drug, Zepbound, for self-pay patients.
The move comes as a recent KFF Health Tracking Poll indicated that a significant portion of GLP-1 drug users pay the full cost themselves due to limited insurance coverage, particularly for weight loss indications. The cost is among the most cited reasons for stopping using the drugs.
Novo Nordisk hopes that these price reductions will make their medications more accessible and affordable, ultimately driving sales and solidifying their position in the increasingly competitive weight loss drug market.
First Piper 